Key personnel acquire warrants, Board member purchases shares

Key personnel in CombiGene AB have acquired the warrants offered by a decision at the Annual Shareholders’ Meeting April 4th. In total, 230 000 warrants were acquired, each giving the warrant holder the right to buy a CombiGene share in May 2019 at a price of 11,1 SEK. May 20th, same day as these transactions, 40 000 shares were acquired on the open market by Board member Lars Thunberg.

The two scientific cofounders David Woldbye and Merab Kokaia acquired 80 000 and 60 000 warrants, respectively. CEO Bengt Westrin acquired 60 000, and CSO Casper Götzsche acquired 30 000. These were the maximum amounts offered, and the subsidiary CombiGene Personal AB which administers this warrant series TO 2 now has 123 760 TO 2 warrants left to be offered as incentives to other key personnel in the future.

The transactions were reported to AktieTorget May 23rd.

For further information:

CombiGene AB (publ)

Bengt Westrin, CEO

Tel: +46 70 265 48 62



Documents & Links